FGF21 and coronary artery disorder: In recent clinical and preclinical studies, CVDs have been closely associated with serum FGF21 which increased in the patients with atherosclerosis, coronary heart disease, myocardial ischemia, cardiac hypertrophy, and diabetic cardiomyopathy [25–27].